Heparin probe finds U.S. tie to Chinese plant
The Wall Street Journal (subscription required), February 15, 2008
Baxter International Inc.'s investigation into the cause of deaths and allergic reactions linked to its blood-thinner heparin is focusing on variations in batches of the active ingredient for the drug, most of which were supplied by a Chinese manufacturing facility co-owned by a Wisconsin company. Baxter said the active ingredient for its heparin was supplied by Scientific Protein Laboratories LLC, a Waunakee, WI, company with a manufacturing facility there and a joint-venture operation called Changzhou SPL in Changzhou, China.
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Carondelet to Pay $35M to Settle Fraud Allegations
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- CA Powers Up $80M HIE to 'Create Value in the Data'
- 3 Traits Personality Assessments Can't Reveal